checkAd
    Teva Pharmaceutical Industries Aktie
    16,610
     
    USD
    -1,60 %
    -0,270 USD
    Letzter Kurs 02:04:00 NYSE
    16,610
     
    USD
    64.200 STK
    Geldkurs 06.06.24
    16,620
     
    USD
    6.900 STK
    Briefkurs 06.06.24
    ISIN: US8816242098 · WKN: 883035 · SYM: TEVA · Israel

    Neueste Nachrichten

    Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    04.06.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY (risperidone) Extended-Release Injectable Suspension from Invega Sustenna (paliperidone palmitate)
    01.06.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
    01.06.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva Announces AUSTEDO XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
    30.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.
    21.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
    15.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
    08.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
    08.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva to Present at the 2024 Bank of America Healthcare Conference
    03.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
    02.05.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab)
    30.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)
    16.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries